Mar 20 2026 This Week in Cardiology

Listener feedback on the nonobstructive HCM trials, AI-enhanced visits, timing of non-culprit PCI in STEMI, new tricuspid valve intervention, and EP at a crossroads are the topics John Mandrola, MD, discusses in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback Koelemen meta-analysis https://www.medrxiv.org/content/10.64898/2026.09.08.26362195v1.full.pdf Improving SCD Risk Stratification in HCM https://pmc.ncbi.nlm.nih.gov/articles/PMC11026183/ II More on Nonobstructive HCM Communication on Post-Hoc Analysis of ODYSSEY (mavacamten) Mavacamten in Nonobstructive HCM 10.1016/j.jacc.2025.12.092 III Complete vs Staged PCI in STEMI With Multivessel Disease Immediate vs Staged CR in Multivessel Disease and STEMI: Meta-Analysis https://doi.org/10.1016/j.jcin.2026.07.033 Timing of Nonculprit PCI for STEMI and Multivessel Disease: Editorial https://doi.org/10.1016/j.jcin.2026.08.009 COMPLETE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1907775 FLOWER MI Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2104650 FRAME AMI Trial https://doi.org/10.1093/eurheartj/ehac763 iMODERN Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2512918 COCUA Trial https://doi.org/10.1016/j.ahj.2023.01.020 MULTISTARS Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307823 OPTION STEMI Trial 10.1016/S0140-6736(25)01529-6 External Link CULPRIT SHOCK Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1710261 BioVasc Trial Substudy https://eurointervention.pcronline.com/article/immediate-versus-staged-complete-revascularisation-in-patients-presenting-with-stemi-and-multivessel-disease Main BioVasc Trial 10.1016/S0140-6736(23)00351-3 External Link FULL REVASC Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2314149 IV A Call to Action for Electrophysiologists Twenty Years at the Crossroads 10.1016/j.jacep.2026.09.023 EP at a Crossroads - Josephson 2007 https://doi.org/10.1016/j.hrthm.2006.12.045 EP at a Crossroads: A Revisit - Josephson 2016 https://doi.org/10.1016/j.hrthm.2016.07.024 V FDA Approves Another Tricuspid Valve Repair System Press release https://www.edwards.com/newsroom/news/2026-10-21-fda-approval-of-edwards-lifesciences--pascal-preci TRIC I HF Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2606934 CLASP II TR Trial https://pubmed.ncbi.nlm.nih.gov/42855029/ The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact [email protected]

Some promising studies in amyloidosis, aficamten in nonobstructive HCM, costs of the microaxial flow pump in cardiogenic shock, and more on the VESALIUS trial of evolocumab are the topics John Mandrola, MD, discusses in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Light Chain Amyloidosis – A Potentially Helpful Drug Anselamimab Does Not Reduce Light-Chain Amyloidosis Deaths https://www.medscape.com/viewarticle/anselamimab-does-not-reduce-light-chain-amyloidosis-deaths-2026a1000z79 II Aficamten in Nonobstructive HCM: The ACACIA trial III Microaxial Flow Pump Cost Analysis of Danger Shock IV More on Evolocumab at ESC: Vesalius Trial Substudies The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact [email protected] https://www.medscape.com/viewarticle/1003092

Listener feedback on POET II, sham control trials in atrial fibrillation, ICDs in HCM, and agenda laundering are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback POET II Response-Tailored or Standard-Duration ABX for Infectious Endocarditis POET I Trial https://www.nejm.org/doi/10.1056/NEJMoa1808312 POET II Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2607887 II PVI-SHAM-AF trial Back in the News GAP-AF Trial https://www.ahajournals.org/doi/10.1161/circep.115.003337 PVI-SHAM-AF Trial 10.1016/S0140-6736(26)01558-8 External Link Why Sham Studies Are a Sham in 2026 10.1016/j.hrthm.2026.09.056 External Link The Indispensable Role of Sham Controls in Evaluating Interventional Therapies 10.1016/j.hrthm.2026.10.001 External Link III ICDs in HCM I CDs for the Prevention of SCD in High-Risk Patients with HCM https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.125.078597 ICDs in HCM: Editorial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.126.079687 IV Agenda Laundering How Commercial “Agenda Laundering” Shapes Critical Care https://www.bmj.com/content/395/bmj-2026-100963 The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact [email protected]

Listener feedback on DANISH-CRT, the POET II trial, a mechanistic study in obesity and AF, the DANCODE trial of slowing CAC progression, and more on GLP-1 drugs are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback DANISH-CRT Trial 10.1016/S0140-6736(26)01597-7 Identifying LV Posterior Wall Delay in RBBB Using Lead V8 https://doi.org/10.1016/j.jacep.2026.03.009 Using Lead V8 as a Tool to Improve Patient Selection in CRT https://doi.org/10.1093/europace/euaf194 II POET II Response-Tailored or Standard-Duration Antibiotics for Endocarditis POET I https://www.nejm.org/doi/10.1056/NEJMoa1808312 POET II https://www.nejm.org/doi/full/10.1056/NEJMoa2607887 III Obesity and AF – A Neat Study from the Team in Prague LA Remodeling and Functional Maladaptations in Obesity https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.126.014509 IV Reducing CAC: The DANCODE Trial DANCODE Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.126.082363 V Two Big RCTs of New GLP-1 Drugs TRIUMPH-1 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2604169 SYNCHRONIZE-2 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2607219 The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact [email protected]

Listener feedback, pulmonary embolism intervention, simple vs complex in BiV pacing, exercise in AF, and TAVR for paradoxical low-flow, low-gradient aortic stenosis are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback LBBP ICD Lead LEADR LBBAP Trial https://pubmed.ncbi.nlm.nih.gov/41110529/ TRIC-I-HF trial TRIC-I-HF Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2606934 Growth of Tricuspid Interventions in Germany https://www.jacc.org/doi/10.1016/j.jcin.2025.05.030 II Treatment of Acute Intermediate-High Risk PE – the PRAGUE-26 Trial PRAGUE-26 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2608012 III Targeting CS leads in CRT devices – DANISH-CRT Trial DANISH-CRT Trial 10.1016/S0140-6736(26)01597-7 IV Exercise for AF, Especially When There Is LA Disease Physical Activity and Risk of Incident AF in Atrial Cardiomyopathy https://www.jacc.org/doi/10.1016/j.jacadv.2026.102999 V Paradoxical Low-Flow, Low-Gradient AS – REBOOT-PARADOX REBOOT-PARADOX trial 10.1016/j.jacc.2026.08.017 ROTAS Trial https://heart.bmj.com/content/110/20/1223 The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact [email protected]